Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options

Idiopathic overactive bladder (OAB) is a chronic condition that negatively affects quality of life, and oral medications are an important component of the OAB treatment algorithm. Recent literature has shown that anticholinergics, the most commonly prescribed oral medication for the treatment of OAB...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Obstetrics and gynecology (New York. 1953) 2021-03, Vol.137 (3), p.454-460
Hauptverfasser: Escobar, Christina M., Falk, Kerac N., Mehta, Shailja, Hall, Evelyn F., Menhaji, Kimia, Sappenfield, Elisabeth C., Brown, Oluwateniola E., Ringel, Nancy E., Chang, Olivia H., Tellechea, Laura M., Barnes, Hayley C., Jeney, Sarah E.S., Bennett, Alaina T., Cardenas-Trowers, Olivia O.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 460
container_issue 3
container_start_page 454
container_title Obstetrics and gynecology (New York. 1953)
container_volume 137
creator Escobar, Christina M.
Falk, Kerac N.
Mehta, Shailja
Hall, Evelyn F.
Menhaji, Kimia
Sappenfield, Elisabeth C.
Brown, Oluwateniola E.
Ringel, Nancy E.
Chang, Olivia H.
Tellechea, Laura M.
Barnes, Hayley C.
Jeney, Sarah E.S.
Bennett, Alaina T.
Cardenas-Trowers, Olivia O.
description Idiopathic overactive bladder (OAB) is a chronic condition that negatively affects quality of life, and oral medications are an important component of the OAB treatment algorithm. Recent literature has shown that anticholinergics, the most commonly prescribed oral medication for the treatment of OAB, are associated with cognitive side effects including dementia. β3-adrenoceptor agonists, the only alternative oral treatment for OAB, are similar in efficacy to anticholinergics with a more favorable side effect profile without the same cognitive effects. However, there are marked cost variations and barriers to access for OAB medications, resulting in expensive copays and medication trial requirements that ultimately limit access to β3-adrenoceptor agonists and more advanced procedural therapies. This contributes to and perpetuates health care inequality by burdening the patients with the least resources with a greater risk of dementia. When prescribing these medications, health care professionals are caught in a delicate balancing act between cost and patient safety. Through multilevel collaboration, we can help disrupt health care inequalities and provide better care for patients with OAB.
doi_str_mv 10.1097/AOG.0000000000004279
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2487150909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2487150909</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4032-e493bf9f173fb01dbf92b10e2978c4c7f82cd9be27267e96a9a876c9e29330253</originalsourceid><addsrcrecordid>eNpdUdtOwkAQ3RiNIPoHxvTRl-Le6HYfkSiSkGAUE9-a7XYqlV5wd4Hw924FL3Fe5nbmzOQMQpcE9wmW4mY4G_fxH-NUyCPUJbFgIWXs9Rh1MaYyFDHnHXRm7bsHkUiyU9RhbMBZLEkXZU_gFkW9LOq34Bl0U2fhtKghmC_AqNUuyBsTzDY-1q7YQHBbqiwDE7gmmFQr0_jSo3IF1C4Yag3Wtp25AeWqtjZbuaKp7Tk6yVVp4eLge-jl_m4-egins_FkNJyGmmNGQ-CSpbnMiWB5iknmY5oSDFSKWHMt8pjqTKZABY0EyEhJFYtISw9gDNMB66HrPa-_7GMN1iVVYTWUpaqhWduE8liQAZZYeijfQ7VprDWQJytTVMrsEoKTVt_E65v819ePXR02rNMKsp-hb0F_ebdN6cDYZbnegkkWoEq3-OKL6ACHFFOCmc_C9imUfQKvZYVW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2487150909</pqid></control><display><type>article</type><title>Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options</title><source>Journals@Ovid Complete</source><creator>Escobar, Christina M. ; Falk, Kerac N. ; Mehta, Shailja ; Hall, Evelyn F. ; Menhaji, Kimia ; Sappenfield, Elisabeth C. ; Brown, Oluwateniola E. ; Ringel, Nancy E. ; Chang, Olivia H. ; Tellechea, Laura M. ; Barnes, Hayley C. ; Jeney, Sarah E.S. ; Bennett, Alaina T. ; Cardenas-Trowers, Olivia O.</creator><creatorcontrib>Escobar, Christina M. ; Falk, Kerac N. ; Mehta, Shailja ; Hall, Evelyn F. ; Menhaji, Kimia ; Sappenfield, Elisabeth C. ; Brown, Oluwateniola E. ; Ringel, Nancy E. ; Chang, Olivia H. ; Tellechea, Laura M. ; Barnes, Hayley C. ; Jeney, Sarah E.S. ; Bennett, Alaina T. ; Cardenas-Trowers, Olivia O.</creatorcontrib><description>Idiopathic overactive bladder (OAB) is a chronic condition that negatively affects quality of life, and oral medications are an important component of the OAB treatment algorithm. Recent literature has shown that anticholinergics, the most commonly prescribed oral medication for the treatment of OAB, are associated with cognitive side effects including dementia. β3-adrenoceptor agonists, the only alternative oral treatment for OAB, are similar in efficacy to anticholinergics with a more favorable side effect profile without the same cognitive effects. However, there are marked cost variations and barriers to access for OAB medications, resulting in expensive copays and medication trial requirements that ultimately limit access to β3-adrenoceptor agonists and more advanced procedural therapies. This contributes to and perpetuates health care inequality by burdening the patients with the least resources with a greater risk of dementia. When prescribing these medications, health care professionals are caught in a delicate balancing act between cost and patient safety. Through multilevel collaboration, we can help disrupt health care inequalities and provide better care for patients with OAB.</description><identifier>ISSN: 0029-7844</identifier><identifier>EISSN: 1873-233X</identifier><identifier>DOI: 10.1097/AOG.0000000000004279</identifier><identifier>PMID: 33543891</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><ispartof>Obstetrics and gynecology (New York. 1953), 2021-03, Vol.137 (3), p.454-460</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><rights>Copyright © 2021 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4032-e493bf9f173fb01dbf92b10e2978c4c7f82cd9be27267e96a9a876c9e29330253</citedby><cites>FETCH-LOGICAL-c4032-e493bf9f173fb01dbf92b10e2978c4c7f82cd9be27267e96a9a876c9e29330253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33543891$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Escobar, Christina M.</creatorcontrib><creatorcontrib>Falk, Kerac N.</creatorcontrib><creatorcontrib>Mehta, Shailja</creatorcontrib><creatorcontrib>Hall, Evelyn F.</creatorcontrib><creatorcontrib>Menhaji, Kimia</creatorcontrib><creatorcontrib>Sappenfield, Elisabeth C.</creatorcontrib><creatorcontrib>Brown, Oluwateniola E.</creatorcontrib><creatorcontrib>Ringel, Nancy E.</creatorcontrib><creatorcontrib>Chang, Olivia H.</creatorcontrib><creatorcontrib>Tellechea, Laura M.</creatorcontrib><creatorcontrib>Barnes, Hayley C.</creatorcontrib><creatorcontrib>Jeney, Sarah E.S.</creatorcontrib><creatorcontrib>Bennett, Alaina T.</creatorcontrib><creatorcontrib>Cardenas-Trowers, Olivia O.</creatorcontrib><title>Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options</title><title>Obstetrics and gynecology (New York. 1953)</title><addtitle>Obstet Gynecol</addtitle><description>Idiopathic overactive bladder (OAB) is a chronic condition that negatively affects quality of life, and oral medications are an important component of the OAB treatment algorithm. Recent literature has shown that anticholinergics, the most commonly prescribed oral medication for the treatment of OAB, are associated with cognitive side effects including dementia. β3-adrenoceptor agonists, the only alternative oral treatment for OAB, are similar in efficacy to anticholinergics with a more favorable side effect profile without the same cognitive effects. However, there are marked cost variations and barriers to access for OAB medications, resulting in expensive copays and medication trial requirements that ultimately limit access to β3-adrenoceptor agonists and more advanced procedural therapies. This contributes to and perpetuates health care inequality by burdening the patients with the least resources with a greater risk of dementia. When prescribing these medications, health care professionals are caught in a delicate balancing act between cost and patient safety. Through multilevel collaboration, we can help disrupt health care inequalities and provide better care for patients with OAB.</description><issn>0029-7844</issn><issn>1873-233X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdUdtOwkAQ3RiNIPoHxvTRl-Le6HYfkSiSkGAUE9-a7XYqlV5wd4Hw924FL3Fe5nbmzOQMQpcE9wmW4mY4G_fxH-NUyCPUJbFgIWXs9Rh1MaYyFDHnHXRm7bsHkUiyU9RhbMBZLEkXZU_gFkW9LOq34Bl0U2fhtKghmC_AqNUuyBsTzDY-1q7YQHBbqiwDE7gmmFQr0_jSo3IF1C4Yag3Wtp25AeWqtjZbuaKp7Tk6yVVp4eLge-jl_m4-egins_FkNJyGmmNGQ-CSpbnMiWB5iknmY5oSDFSKWHMt8pjqTKZABY0EyEhJFYtISw9gDNMB66HrPa-_7GMN1iVVYTWUpaqhWduE8liQAZZYeijfQ7VprDWQJytTVMrsEoKTVt_E65v819ePXR02rNMKsp-hb0F_ebdN6cDYZbnegkkWoEq3-OKL6ACHFFOCmc_C9imUfQKvZYVW</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Escobar, Christina M.</creator><creator>Falk, Kerac N.</creator><creator>Mehta, Shailja</creator><creator>Hall, Evelyn F.</creator><creator>Menhaji, Kimia</creator><creator>Sappenfield, Elisabeth C.</creator><creator>Brown, Oluwateniola E.</creator><creator>Ringel, Nancy E.</creator><creator>Chang, Olivia H.</creator><creator>Tellechea, Laura M.</creator><creator>Barnes, Hayley C.</creator><creator>Jeney, Sarah E.S.</creator><creator>Bennett, Alaina T.</creator><creator>Cardenas-Trowers, Olivia O.</creator><general>Lippincott Williams &amp; Wilkins</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210301</creationdate><title>Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options</title><author>Escobar, Christina M. ; Falk, Kerac N. ; Mehta, Shailja ; Hall, Evelyn F. ; Menhaji, Kimia ; Sappenfield, Elisabeth C. ; Brown, Oluwateniola E. ; Ringel, Nancy E. ; Chang, Olivia H. ; Tellechea, Laura M. ; Barnes, Hayley C. ; Jeney, Sarah E.S. ; Bennett, Alaina T. ; Cardenas-Trowers, Olivia O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4032-e493bf9f173fb01dbf92b10e2978c4c7f82cd9be27267e96a9a876c9e29330253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Escobar, Christina M.</creatorcontrib><creatorcontrib>Falk, Kerac N.</creatorcontrib><creatorcontrib>Mehta, Shailja</creatorcontrib><creatorcontrib>Hall, Evelyn F.</creatorcontrib><creatorcontrib>Menhaji, Kimia</creatorcontrib><creatorcontrib>Sappenfield, Elisabeth C.</creatorcontrib><creatorcontrib>Brown, Oluwateniola E.</creatorcontrib><creatorcontrib>Ringel, Nancy E.</creatorcontrib><creatorcontrib>Chang, Olivia H.</creatorcontrib><creatorcontrib>Tellechea, Laura M.</creatorcontrib><creatorcontrib>Barnes, Hayley C.</creatorcontrib><creatorcontrib>Jeney, Sarah E.S.</creatorcontrib><creatorcontrib>Bennett, Alaina T.</creatorcontrib><creatorcontrib>Cardenas-Trowers, Olivia O.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Escobar, Christina M.</au><au>Falk, Kerac N.</au><au>Mehta, Shailja</au><au>Hall, Evelyn F.</au><au>Menhaji, Kimia</au><au>Sappenfield, Elisabeth C.</au><au>Brown, Oluwateniola E.</au><au>Ringel, Nancy E.</au><au>Chang, Olivia H.</au><au>Tellechea, Laura M.</au><au>Barnes, Hayley C.</au><au>Jeney, Sarah E.S.</au><au>Bennett, Alaina T.</au><au>Cardenas-Trowers, Olivia O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options</atitle><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle><addtitle>Obstet Gynecol</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>137</volume><issue>3</issue><spage>454</spage><epage>460</epage><pages>454-460</pages><issn>0029-7844</issn><eissn>1873-233X</eissn><abstract>Idiopathic overactive bladder (OAB) is a chronic condition that negatively affects quality of life, and oral medications are an important component of the OAB treatment algorithm. Recent literature has shown that anticholinergics, the most commonly prescribed oral medication for the treatment of OAB, are associated with cognitive side effects including dementia. β3-adrenoceptor agonists, the only alternative oral treatment for OAB, are similar in efficacy to anticholinergics with a more favorable side effect profile without the same cognitive effects. However, there are marked cost variations and barriers to access for OAB medications, resulting in expensive copays and medication trial requirements that ultimately limit access to β3-adrenoceptor agonists and more advanced procedural therapies. This contributes to and perpetuates health care inequality by burdening the patients with the least resources with a greater risk of dementia. When prescribing these medications, health care professionals are caught in a delicate balancing act between cost and patient safety. Through multilevel collaboration, we can help disrupt health care inequalities and provide better care for patients with OAB.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>33543891</pmid><doi>10.1097/AOG.0000000000004279</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0029-7844
ispartof Obstetrics and gynecology (New York. 1953), 2021-03, Vol.137 (3), p.454-460
issn 0029-7844
1873-233X
language eng
recordid cdi_proquest_miscellaneous_2487150909
source Journals@Ovid Complete
title Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T08%3A53%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rethinking%20Second-Line%20Therapy%20for%20Overactive%20Bladder%20to%20Improve%20Patient%20Access%20to%20Treatment%20Options&rft.jtitle=Obstetrics%20and%20gynecology%20(New%20York.%201953)&rft.au=Escobar,%20Christina%20M.&rft.date=2021-03-01&rft.volume=137&rft.issue=3&rft.spage=454&rft.epage=460&rft.pages=454-460&rft.issn=0029-7844&rft.eissn=1873-233X&rft_id=info:doi/10.1097/AOG.0000000000004279&rft_dat=%3Cproquest_cross%3E2487150909%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2487150909&rft_id=info:pmid/33543891&rfr_iscdi=true